All the data were analyzed by SPSS version 22.0 software (IBM), X-tile software program (Version 3.6.1; Yale University, School of Medicine), and graphpad prism 5. Continuous variables were compared by Student t test when they were normally distributed, while non-normally distributed we used Wilcoxon rank-sum to test. We used X-tile software program (Version 3.6.1; Yale University, School of Medicine) as described previously[12] to decide the cutoff value of pre-SII, NLR, and PLR. Differences of SII, NLR, PLR between pre-treatments, post-treatments, and recurrent-treatments (rec-treatments) were analyzed by paired T tests. Survival curves were drawn by graphpad prism 5. According to the cutoff value, patients were divided into the following groups: pre-SII ≥ 781.5 group, pre-SII < 781.5 group; pre-NLR ≥ 2.9 group and pre-NLR < 2.9 group; and pre-PLR≥123.2 group and pre-PLR < 123.2 group. The characteristic of each group was shown in Table Table2.2. The Kaplan–Meier method was used to estimate the median value of PFS and OS. The endpoints were OS and PFS. Survival was defined as the time between diagnosis and death or the time of the last follow-up. The PFS time was defined as the time between diagnosis and the patient's recurrence or progression. Cox proportional hazards models were used to identify predictors of other covariates, such as treatment methods, disease stage, doses of radiation, etc. Two-tailed P value <.05 was considered a statistically significant difference.

The relationship between variable SII, NLR, PLR, and clinical characteristics.

NLR = neutrophil-to-lymphocyte ratio, PLR = platelet-lymphocyte ratio, SII = immune-inflammation index, WHO = World Health Organization.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.